Carrie S. Cox is Chairman and Chief Executive Officer of Humacyte, Inc. She joined Humacyte in 2010. Ms. Cox most recently served as Chairman of Prism Pharmaceuticals, sold to Baxter Corporation in 2011. Ms. Cox was EVP and President, Global Pharmaceuticals, at Schering-Plough Corporation, from 2003 until its merger with Merck & Co., Inc., in November 2009. She was responsible for the company’s global prescription pharmaceutical business, which generated approximately $16 billion in annual sales, with a five-year CAGR of 22%. Prior to that, she held a similar role as President, Global Prescription Business at Pharmacia Corporation. Previously, Cox served as SVP of Global Business Management at Pharmacia & Upjohn (the predecessor company to Pharmacia), and as VP of Women’s Healthcare at Wyeth-Ayerst. Cox spent her early career at Sandoz pharmaceuticals (now Novartis) in a variety of commercial roles of increasing responsibility. Cox currently serves on the Boards of Directors of Texas Instruments, Cardinal Health, and Celgene, and she has served as Lead Director for Texas Instruments. Cox has been named six times to FORTUNE Magazine’s list of the “50 Most Powerful Women in Business” and she was named to “Top 10 Women in Biotech” by Fierce Biotech publications in 2012. Her work has been featured in the Harvard Business Review and in the New York Times bestseller, The Profit Zone. She received her B.S. from Massachusetts College of Pharmacy, and worked for several years in retail and hospital pharmacy.